Vaxxel is a preclinical-stage company developing vaccines against the main cause of bronchiolitis and viral pneumonia: human Respiratory Syncytial Virus (RSV) and human Metapneumovirus (hMPV)
Vaxxel develops intranasal live-attenuated vaccines (LAVs) derived from a proprietary technology based on (i) Metavac®, a genetically modified HMPV developed by the Virology Laboratory of Lyon University, and (ii) a GMP grade Vero cell line permissive to HMPV
Two vaccine candidates are in development with expected higher- and longer duration of- protection, and reduced viral trabnsmission, addressing a market of >$5bn:
Metavac®-RSV, a first-in-class bivalent HMPV-RSV Intranasal (IN) vaccine candidate with in vivo preclinical PoC in two animal models, and
a monovalent HMPV IN vaccine candidate with preclinical in vivo PoC
Vaxxel is preparing for a Series A funding round of 8m€ in Q1 2025